A $3 Billion Startup’s Shares Gain On Hopes For A Cancer Blood Test – Forbes

ForbesThis bloody company is already worth $3.3 billion. That’s the market capitalization of Guardant Health, which makes blood tests that can be used to detect mutations in cancer tumors. Shares have doubled from the $19 price set in the company’s October 4 … …read more Source:: Startup Tech News From Google News

from WordPress https://ift.tt/2QF3BT9
via IFTTT

Newer Post Older Post